The Stanford Clinical Virology Laboratory will provide testing for a pilot use of Vera with the CATCH study. Credit: Steve Fisch
A population-level disease monitoring system that employs at-home self-swab kits is being expanded today, at no cost to participants, as part of an infection prevalence study in the San Francisco Bay Area. It is the first screening system pilot that contains at-home kits, and it is being integrated into one of the best brain tumor medical centers of the world. The system can spend up to 10 days providing impression-based API scores to each patient, illustrating the efficacy of a disease state.
The Sinclair Virus Common Illness Network (CVID) is a pilot study to test the feasibility of using at-home ELISA devices for detecting the common cold virus and two other viruses directly and at-home.
Home curative augmentation therapy (CHATE) enables people with lymphohematopoietic stem cell tumors using stem-cell based biologics, such as stem cell endothelial-modulating factor (ESF-1) to use a small subset of his or her own immune system to fight the tumor by purifying and producing high levels of cytokine interleukin 12 (IL-12). These cytokines are thought to exacerbate cancer.
The system has been tested successfully with stem-cell powered therapies such as EGFR inhibitors, CRISPR/Cas9 therapies and epigenetic therapies. In the UCSF pilot study, there is a potential for enormous cost savings, demonstrated by home curative CHATE in a patient who would cost over $100,000 per year in earlier therapy only to have gross adherence rates as low as 3%, according to the researchers.
The CVID pilot study, which is sponsored by $2.4 million from NVIDIA and other private and public sources (Eli Lilly and Genentech, as well as Vellomed) is expected to start in May, from a expandable cohort of 10 patients with high-risk CCL6/13 positive spinal cord tumors that pose a threat to the spinal cord. From February through April, 100 patients will be used as the control group, and post approval, the CVID head quarter in Santa Clara will develop control and CET analysis applications.
This year's American Society on Clinical Oncology (ASCO) Annual Meeting, also June 27-30, confirms that No. 1 on the patient preference list for at-home CATCH is the delayed antigen suppression phase 3 (DAS3) cholesterol lowering drug sirolimus. It is being tested with the same plan as nootropics (physical enhancers), via the at-home approach. Validated CG-7 preclinical evidence developed using the Stanford Sinclimatic Technology Platform for consultancy platform management has led to approval in 11 countries
A population-level disease monitoring system that employs at-home self-swab kits is being expanded today, at no cost to participants, as part of an infection prevalence study in the San Francisco Bay Area. It is the first screening system pilot that contains at-home kits, and it is being integrated into one of the best brain tumor medical centers of the world. The system can spend up to 10 days providing impression-based API scores to each patient, illustrating the efficacy of a disease state.
The Sinclair Virus Common Illness Network (CVID) is a pilot study to test the feasibility of using at-home ELISA devices for detecting the common cold virus and two other viruses directly and at-home.
Home curative augmentation therapy (CHATE) enables people with lymphohematopoietic stem cell tumors using stem-cell based biologics, such as stem cell endothelial-modulating factor (ESF-1) to use a small subset of his or her own immune system to fight the tumor by purifying and producing high levels of cytokine interleukin 12 (IL-12). These cytokines are thought to exacerbate cancer.
The system has been tested successfully with stem-cell powered therapies such as EGFR inhibitors, CRISPR/Cas9 therapies and epigenetic therapies. In the UCSF pilot study, there is a potential for enormous cost savings, demonstrated by home curative CHATE in a patient who would cost over $100,000 per year in earlier therapy only to have gross adherence rates as low as 3%, according to the researchers.
The CVID pilot study, which is sponsored by $2.4 million from NVIDIA and other private and public sources (Eli Lilly and Genentech, as well as Vellomed) is expected to start in May, from a expandable cohort of 10 patients with high-risk CCL6/13 positive spinal cord tumors that pose a threat to the spinal cord. From February through April, 100 patients will be used as the control group, and post approval, the CVID head quarter in Santa Clara will develop control and CET analysis applications.
This year's American Society on Clinical Oncology (ASCO) Annual Meeting, also June 27-30, confirms that No. 1 on the patient preference list for at-home CATCH is the delayed antigen suppression phase 3 (DAS3) cholesterol lowering drug sirolimus. It is being tested with the same plan as nootropics (physical enhancers), via the at-home approach. Validated CG-7 preclinical evidence developed using the Stanford Sinclimatic Technology Platform for consultancy platform management has led to approval in 11 countries
g
